CHANGES IN THE HAEMOSTASIS SYSTEM OF PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE LIVER ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE by Nataliia Matkovska
WORLD SCIENCE                                                                                                                          ISSN 2413-1032 
 
22 № 6(46), Vol.3, June 2019                                                                                  
 
CHANGES IN THE HAEMOSTASIS SYSTEM OF 
PATIENTS WITH ALCOHOLIC CIRRHOSIS OF THE 
LIVER ASSOCIATED WITH NON-ALCOHOLIC FATTY 
LIVER DISEASE 
 
Assosiate Professor Nataliia Matkovska 
Ukraine, Ivano-Frankivsk, Ivano-Frankivsk National Medical University; 
Department of Therapy and Family Practice of postgraduate study faculty 
 
DOI: https://doi.org/10.31435/rsglobal_ws/30062019/6572 
 
ARTICLE INFO 
Received: 28 April 2019 
Accepted: 23 June 2019 
Published: 30 June 2019 
 
ABSTRACT 
The purpose of the research was to study the changes in haemostatic system 
in patients with alcohol liver disease (ALD) associated with NAFLD. The 
decrease in the synthetic function of the liver and the development of 
hypersensitivity syndrome in patients with ALC in combination with 
NAFLD is accompanied by more pronounced changes in the various parts of 
the haemostasis of the corresponding Child-Pugh class, which manifests 
itself in the decrease in the number of blood corpuscles, PI levels, and 
growth of indicators for D-dimers, INR, Von Willebrand factor, PT, TT, 
APTT. Such changes lead to hypo- and hypercoagulation states, which may 
be accompanied by complications such as thrombosis and bleeding. 
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Introduction. In recent years, the problems of pathogenesis, diagnostics and correction of 
disorders of the haemostasis system have attracted the attention of scientists more often. This is 
especially true for diseases that are accompanied by haemostasis disorders [1]. The liver affects on all 
components of haemostasis, it plays a significant role in regulation of this system, maintenance of the 
liquid state of the blood and keeping it within the vascular bed, by maintaining a balance between the 
thrombotic factors and the components responsible for blood flow. This balance is supported by the 
interaction of the coagulation cascade of platelets (blood coagulation system), vascular walls, and on the 
other hand – anticoagulative mechanisms and the fibrinolysis system [2, 3, 4]. Dystrophic and necrotic 
changes of hepatocytes, and especially such irreversible changes as disorders of the hepatic tissue 
architectonics, are the cause of the clinical and laboratory manifestation of the disease and determine the 
degree of severity and the rate of progression of the pathological condition [5, 6]. In hepatocytes, all 
proteins of the coagulative system are synthesized; these are procoagulants (with the exception of the 
Von Willebrand factor and blood clotting factor VIII), coagulation inhibitors (antithrombin III, proteins 
C, S, α2-macroglobulin, α-antitrypsin, etc.), [7, 8]. According to the literature, liver cirrhosis (LC) is 
characterized by a decrease in the number of such proteins in different proportions, which leads to an 
imbalance of procoagulants and anticoagulants. In this case, the more severe course of the disease 
correlates with a decrease in the number of inhibitors of coagulation, which causes the state of 
thrombophilia [9, 10, 11]. Therefore, researchers reveal both the states of hypocoagulation and 
hypercoagulation at the LC, which is the cause of intrahepatic and extrahepatic thromboses and leads to a 
steady progression of the LC and the development of fatal complications [12, 13, 14]. 
LC is one of the main causes of disability and mortality in economically developed countries [15]. 
The alcoholic etiology of the LC is the most common, however, in recent years, the problem of the growth 
of non-alcoholic fatty liver disease (NAFLD), which is accompanied by systemic disorders, in particular 
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lipid and carbohydrate imbalances, has been widely studied. Such changes adversely affect the involvement 
of various systems and organs, as well as the growth rate of the disease progression and the development of 
multiple organ failure [16]. The risk of bleeding from varicose veins of the esophagus and the stomach, 
which is caused by a significant increase in pressure in the portal system due to the development of portal 
crises, dystrophic changes in the esophagus and stomach mucous membrane, and disorders in the 
haemostasis system, are considered to be a dangerous prognostic risk [17]. Therefore, it is important to 
study the various parts of the system of haemostasis and the possibility of correction of their disorders. 
The purpose of the research was to study the changes in haemostatic system in patients with 
alcohol liver disease (ALD) associated with NAFLD. 
Materials and methods. 204 patients with diagnosed LC participated in the study; they underwent 
inpatient treatment in the gastroenterology department of the Ivano-Frankivsk Regional Clinical Hospital. 
Among them, 78 patients were diagnosed with ALD at the stage of the LC (group I) and 126 patients had a 
combination of alcoholic liver cirrhosis (ALC) and NAFLD (group II). Among the patients in group I, 
there were 24 women and 54 men (53.2±11.4) years old and average duration of the disease (5.9±2.1) 
years; among patients of group II there were 22 women and 104 men (47.8±9.4) years old and average 
duration of the disease (4.2±2.7) years. Patients of groups I and II were subgrouped according to the 
compensation classes of LC by Child-Pugh score: IA (17 persons), IB (38 persons), IC (23 persons); IIA 
(44 persons), IIB (48 persons), IIC (34 persons). The body mass index (BMI) of patients in ІА, ІВ, ІС and 
ІІА, ІІB, ІІC groups was (22.61 ± 2.15), (21.04 ± 1.52), (19.21 ± 1.63) and (34.56 ± 4.67), (30.83 ± 2.87), 
(21.35 ± 1.63) kg/m2, respectively. Diagnosis was verified using clinical and laboratory-instrumental 
methods in accordance with the order of the Ministry of Health of Ukraine No. 826 dated November 6, 
2014, adapted clinical guidelines "Non-Alcoholic Fatty Liver Disease", 2014, adapted clinical guidelines 
"Alcoholic Liver Disease", 2014, adapted clinical guidelines " Liver Cirrhosis, 2017 (State Expert Centre of 
the Ministry of Health of Ukraine, Ukrainian Gastroenterology Association, Kyiv), recommendations of 
the European Association for the Study of Liver, Diabetes and Obesity (EASL-EASD-EASO, 2016). 
A general-clinical examination, ultrasound examination of the abdominal cavity and 
esophagogastroduodenoscopy were performed. To detect the alcoholic aetiology of the disease, according to 
the recommendations of the World Health Organization, more than 2 doses of alcohol (1 standard dose = 10 g 
of ethyl alcohol) per day for women and more than 4 doses for men, were taken into account. CAGE (Cut, 
Annoyed, Guilty, Eye-opener), AUDIT (Alcohol Use Disorders Identification Test, 1989), the PAS 
questionnaire (post-alcohol syndrome developed by P.P Ogurtsov, A.B. Pokrovsky, A.E Uspensky), LeGo 
(P.M LeGo 1976) in the modification of O.B. Zharkov, 2000), ANI index (Alcoholic liver disease/non-
alcoholic fatty liver disease index, 2006) were used. The protein-synthetic function of the liver was 
determined by the level of albumin, fibrinogen in blood, prothrombin index (PI) and international normalized 
ratio (INR). Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and 
fibrinogen were measured using conventional methods. The content of plasmin degradation product of the 
insoluble D-dimer product fibrin (DD) was measured by immunoassay using “Technozym D-dimer ELISA”, 
respectively (“Technoclone”, Austria). Prothrombin time (PT), activated partial thromboplastin time (APTT), 
thrombin time (TT) and fibrinogen were measured using conventional methods. The Willebrand factor was 
determined by the method based on the stimulation of ristomycin aggregation (suspension of fixed donor 
platelets by the Willebrand factor of the study without platelet plasma). Calculation was carried out on a 
calibration curve built on logarithmic paper. For its construction, 20 donor platelet-poor plasmas were diluted 
1:1, 1:2, 1:4, 1:5, corresponding to a concentration of 100%, 50%, 25%, 12.5% of the Willebrand factor in 
blood plasma. To increase the accuracy of the analysis, two parallel samples were tested, followed by an 
average value calculation. The control group included 20 practically healthy persons. 
Exclusion criteria were liver cirrhosis of the viral, toxic and autoimmune genesis, metabolic 
diseases of the liver, oncological diseases, and the lack of individual consent of the patient to conduct the 
study. All patients were matched according to age and sex. The research was carried out in accordance with 
the ethical principles of conducting scientific research and principles of the Helsinki Declaration. 
Statistical processing of the obtained results was carried out using the software package 
Statistica v. 12.0, StatSoft, USA and Microsoft Exel. The parameters of parametric statistics were used 
– the arithmetic average (M) and the standard deviation (SD). To determine the significance of the 
differences between groups in the distribution, close to normal, t-criterion Student was used. 
Statistically significant differences were considered at p <0.05. 
Research results. Analyzing the data of the clinical examination, it was found that the 
symptoms of astheno-vegetative, painful, dyspeptic, hepatorenal, hepatopulmonary syndromes, 
jaundice, medically uncontrolled ascites, signs of hepatic encephalopathy were more common in 
patients of group II of the corresponding classes. Among hemorrhagic complications there was 
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bleeding from esophageal varices. 19 (31.1%) and 31 (37.8%) persons of ІВ (8/21.1) + С (11/47.8) 
and ІІВ (12/25) + С (19/55.9) groups respectively, suffered from bleeding esophageal varices. 
Splenomegaly syndrome was clinically manifested by an increase in the size of the spleen in 
58.8%, 75%, 71.1%, 89.6% of patients of IA, IIA, IB, IIB groups, respectively, and in all patients of IC and 
IIC groups. Laboratorially, the splenomegaly syndrome was manifested by a decrease in the number of 
platelets and erythrocytes. In patients of group II, such changes were more pronounced (Table 1). 
The results of the biochemical study showed that the parameters of the synthetic function of the liver 
in patients of Group II was more pronounced decrease compared to patients in Group I, which is reflected in 
lowering the albumin content in the blood, fibrinogen and PI (ІІА – by 9.1%, 9.1%, 5.5%, 13.4%, IIC – by 
12.5%, 19.2%, 9.6%, 15.1%, ІІС – by 16.1%, 14.3%, 9.1%, 9.9% respectively, all p<0.05). 
The content of D-dimers was higher in patients of group II than in patients of group І for 
Child-Pugh class A – by 11.11% (p<0.05); class B – by 16.67% (p<0.05), and did not differ 
significantly in the terminal stage of ALC for C class (p>0.05). The levels of INR increased with 
increasing decompensation of ALC (p<0.05), which indicates liver dysfunction; its differences in 
patients of both groups were not detected (p>0.05). 
The number of platelets decreased with the progression of the disease and was lower in 
patients of IIA, IIB and IIC groups by 25.5%, 19.5% and 24.2%, respectively, compared to patients in 
group I of the corresponding classes. The number of erythrocytes also decreased with decompensation 
of the disease and was lower in patients of IIA, IIB and IIC groups by 5.3%, 19.5% and 14.5%, 
respectively, compared to patients in group I of the corresponding classes. 
Level of Von Willebrand factor increases with progression of the disease. In particular, in 
patients of IIA, IIB and IIC groups, this indicator was higher by 10.7%, 22.7% and 10.5%, 
respectively, compared with patients in group I of the corresponding classes. 
Indicators of PT, APTT and TT increased with progression of the disease. In patients of IIA, IIB 
and IIC groups, the levels of PT were 16.1%, 13.8% and 11.5% higher than those in patients of group I of 
the corresponding classes. Indicators of APTT in patients of IIA, IIB and IIC groups was 9.5%, 17% and 
24.2% higher than those in group I of the corresponding classes. TT values in patients of IIA, IIB and IIC 
groups were 9%, 10.1% and 7.5% higher than those in group I of the corresponding classes. 
Table 1. Indicators of the synthetic function of the liver and disorders of haemostatic system in 
patients with alcoholic liver cirrhosis depending on the concomitant non-alcoholic fatty liver disease 
and Child-Pugh class, Мm 
Parameters 
(Mean ±SD)  
Healthy  
n=20 
Class А  Class В  Class С  
Group І, 
n=17 
Group ІІ, 
n=44 
Group І, 
n=38 
Group ІI, 
n=48 
Group І, 
n=23 
Group 
ІI, n=34 
Total protein, g/l 74.67± 
4.27 
62.12± 
5.74* 
59.92± 
2.56* 
56.46± 
2.24*◊ 
52.72± 
2.16*◊ 
46.35± 
2.71*●# 
42.18± 
1.53*# 
Albumin, g/l  47.83± 
4.26 
43.37± 
1.86*● 
39.43± 
1.09* 
34.61± 
1.75*●◊ 
30.28± 
1.58*◊ 
28.82± 
1.74*●# 
24.17± 
1.65*# 
Fibrinogen, g/L 3.66 
0.27 
2.74± 
0.09*● 
2.49± 
0.07* 
2.14± 
0.12*●◊ 
1.73± 
0.14*◊ 
1.61± 
0.13*●# 
1.38± 
0.11*# 
Erythrocytes, *10
12/l 
4.68 
0.31 
4.16 
0.36 
3.95 
0.34* 
3.85 
0.27*● 
3.22 
0.25*◊ 
2.45 
0.14*●# 
2.14 
0.13*# 
Platelets, *109/l 254.13± 
15.63 
204.38± 
12.72*● 
162.43± 
10.34* 
153.29± 
9.78*●◊ 
128.31± 
10.23*◊ 
116.94± 
7.36*●# 
94.15± 
8.87*# 
Von Willebrand 
factor, % 
102.31± 
4.51 
115.82± 
5.26*● 
128.19± 
6.31* 
137.26± 
4.95*●◊ 
168.37± 
5.26*◊ 
197.52± 
7.41*●# 
218.34± 
6.07*# 
PT (sec) 11.27+ 
0.69 
12.62± 
0.71* 
14.65± 
0.84*• 
15.09± 
0.67*◊ 
17.18+ 
0.72*•◊ 
19.84± 
0.75*# 
22.12+ 
0.86*•# 
APTT (sec) 27.76± 
1.35 
33.07± 
1.38* 
36.21± 
1.53* 
36.84± 
1.62*◊ 
43.12± 
1.97*•◊ 
44.63± 
1.71*# 
55.42± 
2.13*•# 
TT (sec) 16.79± 
0.82 
18.56± 
0.73* 
20.24± 
0.85* 
21.46± 
0.94*◊ 
23.67± 
1.19*•◊ 
23.91± 
1.27*# 
25.71± 
1.24*# 
INR 1.21± 
0.08 
1.34± 
0.07*● 
1.52± 
0.12* 
1.85± 
0.11*●◊ 
2.13± 
0.09*◊ 
2.51± 
0.14*●# 
2.76± 
0.10*# 
PI, % 88.52± 
5.73 
75.58± 
1.34*● 
71.43± 
1.47* 
62.27± 
1.99*●◊ 
56.32± 
1.58*◊ 
38.18± 
1.86*●# 
34.71± 
1.42*# 
D-dimer, ng/ml 0.29± 
0.01 
0.45± 
0.01* 
0.50± 
0.01*• 
0.60± 
0.03*◊ 
0.72± 
0.04*•◊ 
0.84± 
0.04*# 
0.95± 
0.06*•# 
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Notes: * – the reliability of the differences between Groups ІI and І compared with healthy persons, • 
– the reliability of the indicators difference in Group I compared with Group II of the corresponding 
Child-Pugh Classes, ◊ – the reliability of the indicators difference of Class B compared with Class A 
in Groups II and I, respectively, p<0.05; # – the reliability of the indicators difference of Class C 
compared with Class A in Groups II and I, respectively, p<0.05;  the reliability of the indicators 
difference of Class C compared with Class B in Groups II and I, respectively, p<0.05.  
Thus, a decrease in the synthetic function of the liver and the development of hypersensitivity 
syndrome in patients with ALC in combination with NAFLD is accompanied by more pronounced changes 
in the various parts of the haemostasis of the corresponding Child-Pugh class, which manifests itself in the 
decrease in the number of blood corpuscles, PI levels, and growth of indicators for D-dimers, INR, Von 
Willebrand factor, PT, TT, APTT. Such changes lead to hypo- and hypercoagulation states, which may be 
accompanied by complications such as thrombosis and bleeding. 
Conclusions. Patients with ALC associated with NAFLD have more pronounced changes in 
various haemostasis stages: procoagulant and anticoagulant factors. In particular, the levels of PI and 
blood corpuscles decrease, while the D-dimers, INR, Von Willebrand factor, PT, TT, and APTT 
indices are increasing. 
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